gms | German Medical Science

25. Jahrestagung der Regionalgesellschaft der Augenärzte Sachsen-Anhalts und Thüringens (SATh 25)

01.09. - 02.09.2017, Jena

Effectiveness of intracameral dexamethasone injection in immune reaction after penetrating and posterior lamellar keratoplasty

Meeting Abstract

  • Miltiadis Fiorentzis - Halle/Saale
  • A. Viestenz - Halle/Saale; Homburg/Saar
  • A. Viestenz - Halle/Saale
  • S. Bäurle - Halle/Saale
  • B. Seitz - Homburg/Saar

Regionalgesellschaft der Augenärzte Sachsen-Anhalts und Thüringens. 25. Jahrestagung der Regionalgesellschaft der Augenärzte Sachsen-Anhalts und Thüringens. Jena, 01.-02.09.2017. Düsseldorf: German Medical Science GMS Publishing House; 2017. Doc17sath25

doi: 10.3205/17sath25, urn:nbn:de:0183-17sath258

Veröffentlicht: 28. August 2017

© 2017 Fiorentzis et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe



Purpose: The aim of this observational study is to evaluate the effectiveness of an adjuvant intracameral corticosteroid injection (ICI) in cases of severe endothelial immune reaction (SEIR) (anterior chamber cells and flare, retrocorneal precipitates, Descemet's folds and corneal edema) after penetrating keratoplasty (PKP) and posterior lamellar keratoplasty (PLK).

Methods: In this retrospective study, 24 subjects treated between November 2011 to September 2014 were divided into two groups. The control group received topical and systemic steroid therapy while the study group received additionally ICI (400µg dexamethasone). Outcome measures included changes in best corrected visual acuity (BCVA), central corneal thickness (CCT, Pentacam), endothelial cell count (ECC) and intraocular pressure (IOP). The follow-up examinations were conducted after a period of 6 weeks and 3 months. Results were compared using the Wilcoxon signed-rank test.

Results: BCVA of the patients in the study group increased from logMAR 1.5 ± 0.77 at baseline to 0.99 ± 0.44 (p=0.009) at six weeks and to 0.78 ± 0.45 (p=0.017) at three months following the ICI. The CCT decreased from to 835 ± 211 µm at baseline to 609 ± 63 µm (p=0.005) after 3 months. ECC showed a significant reduction 12 weeks after treatment in both groups (p=0.012 in the control group and p=0.005 in the study group). This reflects a mean ECC loss of 17% and 19% due to the immune reaction in the control and study group respectively. A significant temporary increase in the IOP was documented only in the control group (p=0.005).

Conclusion: The ICI seems to be a safe adjuvant approach, which improves therapeutic efficacy of SEIR after keratoplasty.